Spero Therapeutics Inc (SPRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.26M
Last updated: Nov 17, 2026 at 11:05 AM ET
Spero Therapeutics Inc (SPRO) Financials: Revenue, Profit and Cash Flow
Spero Therapeutics reported revenue of $66.80M for the fiscal year ended Dec 31, 2025, up 39.2% from the year before. That year, net income was $8.57M with a net margin of 12.8%, operating cash flow was -$12.62M and free cash flow was -$12.62M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$44.28M.
Revenue and Margins
The operating margin was 9.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $335.00K, a compound annual rate of 80.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $66.80M | +39.2% | 100.0% | 9.5% | 12.8% |
| Dec 2024 | $47.98M | -53.8% | 100.0% | -152.9% | -142.9% |
| Dec 2023 | $103.78M | +94.0% | 100.0% | 20.7% | 22.0% |
| Dec 2022 | $53.51M | +193.1% | 100.0% | -78.9% | -86.7% |
| Dec 2021 | $18.26M | +95.7% | 100.0% | -481.9% | -491.7% |
| Dec 2020 | $9.33M | -49.2% | 100.0% | -847.9% | -839.0% |
| Dec 2019 | $18.37M | +363.2% | 100.0% | -344.1% | -331.7% |
| Dec 2018 | $3.97M | +100.4% | 100.0% | -1079.3% | -1050.5% |
| Dec 2017 | $1.98M | +490.7% | 100.0% | -2108.6% | -2015.5% |
| Dec 2016 | $335.00K | N/A | 100.0% | -9916.7% | -9743.6% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.80M | $47.98M | $103.78M | $53.51M | $18.26M | $9.33M | $18.37M | $3.97M | $1.98M | $335.00K |
| Gross profit | $66.80M | $47.98M | $103.78M | $53.51M | $18.26M | $9.33M | $18.37M | $3.97M | $1.98M | $335.00K |
| Research and development | $38.47M | $96.76M | $51.44M | $47.59M | $64.53M | $67.00M | $65.78M | $33.88M | $32.87M | $26.33M |
| Operating income | $6.31M | -$73.36M | $21.48M | -$42.20M | -$87.97M | -$79.11M | -$63.22M | -$42.81M | -$41.73M | -$33.22M |
| Net income | $8.57M | -$68.57M | $22.81M | -$46.41M | -$89.76M | -$78.28M | -$60.92M | -$41.66M | -$39.89M | -$32.64M |
| EBITDA | $6.32M | -$73.30M | $21.83M | -$40.45M | -$87.27M | -$77.95M | -$62.48M | N/A | -$39.83M | -$32.36M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $258.00K | $41.30M | $5.44M | $14.19M | $5.87M | $15.04M | $13.47M | $10.20M | $9.27M | $73.52M |
| Gross profit | $0 | $0 | $258.00K | $41.30M | $5.44M | $14.19M | $5.87M | $15.04M | $13.47M | $10.20M | $9.27M | $73.52M |
| Operating income | -$41.91M | -$9.93M | -$7.54M | $31.41M | -$7.92M | -$2.44M | -$14.73M | -$21.73M | -$18.59M | -$19.06M | -$13.98M | $50.53M |
| Net income | -$44.28M | -$9.55M | -$7.20M | $31.52M | -$7.38M | -$1.70M | -$13.87M | -$20.89M | -$17.15M | -$17.86M | -$12.67M | $51.19M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $2.05M by $38.22M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $68.92M | $110.54M | $182.39M | $124.80M | $171.07M | $153.45M | $106.10M | $129.01M | $93.48M | $13.77M |
| Current assets | $67.29M | $107.28M | $131.21M | $113.57M | $157.87M | $139.15M | $95.41M | $124.22M | $92.06M | $11.87M |
| Cash and equivalents | $40.27M | $52.89M | $76.33M | $109.11M | $112.58M | $85.21M | $29.73M | $34.08M | $87.29M | $10.31M |
| Total liabilities | $9.90M | $64.42M | $75.50M | $48.87M | $82.78M | $21.41M | $31.53M | $13.15M | $8.52M | $7.41M |
| Short-term debt | $1.96M | $1.75M | $1.72M | $1.69M | $1.36M | $947.00K | $928.00K | $223.00K | $223.00K | N/A |
| Long-term debt | $91.00K | $0 | $87.00K | $96.00K | $138.00K | $177.00K | $249.00K | N/A | $0 | N/A |
| Shareholder equity | $59.02M | $46.12M | $106.89M | $75.93M | $88.29M | $132.04M | $74.57M | $115.50M | $84.60M | -$45.44M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $110.03M | $52.77M | $59.02M | $68.92M | $54.17M | $62.12M | $77.71M | $110.54M | $135.16M | $149.88M | $167.70M | $182.39M |
| Total liabilities | $109.25M | $8.56M | $6.09M | $9.90M | $27.68M | $29.29M | $43.90M | $64.42M | $69.65M | $69.38M | $71.45M | $75.50M |
| Cash and equivalents | $107.93M | $50.77M | $56.13M | $40.27M | $48.62M | $31.19M | $48.89M | $52.89M | $76.29M | $63.53M | $82.27M | $76.33M |
| Shareholder equity | $781.00K | $44.20M | $52.93M | $59.02M | $26.49M | $32.83M | $33.81M | $46.12M | $65.51M | $80.50M | $96.25M | $106.89M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.62M | -$23.44M | -$32.99M | -$7.73M | -$64.35M | -$85.87M | -$50.02M | -$39.63M | -$39.11M | -$28.96M |
| Capital expenditures | $0 | $0 | $0 | $0 | $64.35M | $157.00K | $314.00K | $2.44M | $27.00K | $830.00K |
| Free cash flow | -$12.62M | -$23.44M | -$32.99M | -$7.73M | -$128.69M | -$86.03M | -$50.33M | -$42.06M | -$39.14M | -$29.79M |
| Dividends paid | N/A | N/A | N/A | $54.48M | $47.48M | N/A | N/A | N/A | $1.18M | $0 |
| Share repurchases | N/A | N/A | N/A | $0 | $248.00K | $953.00K | $158.00K | $1.31M | $3.57M | $0 |
| Investing cash flow | $0 | $0 | $0 | $33.81M | $7.67M | $10.47M | $29.53M | -$83.16M | -$27.00K | -$830.00K |
| Financing cash flow | $0 | $0 | $221.00K | -$29.55M | $84.05M | $130.88M | $16.14M | $69.52M | $116.11M | $34.41M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$42.61M | -$5.36M | $15.86M | -$8.35M | $17.42M | -$17.69M | -$4.00M | -$23.40M | $12.76M | -$18.74M | $5.94M | -$17.49M |
| Free cash flow | N/A | N/A | $15.86M | -$8.35M | $17.42M | -$17.69M | -$4.00M | -$23.40M | $12.76M | -$18.74M | $5.94M | -$17.49M |
Frequently Asked Questions About SPRO
What is Spero Therapeutics' annual revenue?
Spero Therapeutics reported revenue of $66.80M for the fiscal year ended Dec 31, 2025.
How fast is Spero Therapeutics' revenue growing?
Revenue was up 39.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 7.7%.
Is Spero Therapeutics profitable?
Yes. Spero Therapeutics reported net income of $8.57M for the fiscal year ended Dec 31, 2025, with a net margin of 12.8%.
How much free cash flow does SPRO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.62M minus capital expenditures of $0 produced free cash flow of -$12.62M.
How much debt does Spero Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $91.00K, short-term debt of $1.96M and cash and equivalents of $40.27M.
SPRO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts